Midatech Pharma PLC 2017 Annual Report and AGM Notification (9717P)
June 01 2018 - 1:00AM
UK Regulatory
TIDMMTPH
RNS Number : 9717P
Midatech Pharma PLC
01 June 2018
1 June 2018
Midatech Pharma PLC
("Midatech", "Company" or "Group")
2017 Annual Report and AGM Notification
Midatech (AIM: MTPH, Nasdaq: MTP), the international specialty
pharmaceutical company focused on developing and commercialising
products in oncology and immunotherapy, is pleased to confirm that
the 2017 Annual Report for the year ended 31 December 2017 has been
sent to shareholders. The document is available today on the
"Investors" section of the Company's website at
http://www.midatechpharma.com/investors/financial-reports.html.
Midatech also announces that its AGM will be held on Wednesday
27 June 2018. The meeting will be held at Panmure Gordon & Co,
1 New Change, EC4M 9AF, London, commencing at 9:30 a.m.
- Ends -
For more information, please contact:
Midatech Pharma PLC
Dr Craig Cook, CEO
Nick Robbins-Cherry, CFO
+44 (0)1235 888 300
www.midatechpharma.com
Panmure Gordon (UK) Limited (Nominated Adviser and Broker)
Freddy Crossley / Emma Earl / Ryan McCarthy
+44 (0)20 7886 2500
Consilium Strategic Communications (Financial PR)
Mary Jane Elliott / Ivar Milligan / Nicholas Brown
+44 (0)20 3709 5700
midatech@consilium-comms.com
Westwicke Partners (US Investor Relations)
Chris Brinzey
+1 339 970 2843
chris.brinzey@westwicke.com
Notes for Editors
About Midatech Pharma PLC
Midatech is an international specialty pharmaceutical company
focused on the research and development of a pipeline of medicines
for oncology and immunotherapy. Midatech's strategy is to
internally develop oncology products, and to drive growth both
organically and through strategic acquisitions. The Company's
R&D activities are focused on three innovative platform
technologies to deliver drugs at the "right time, right place":
gold nanoparticles ("GNPs") to enable targeted delivery; Q-Sphera
polymer microspheres to enable sustained release ("SR") delivery;
and Nano Inclusion ("NI") to provide local delivery of
therapeutics, initially to the brain. Midatech Pharma US is the
Group's US commercial operation, with four cancer supportive care
products. The Group, listed on AIM: MTPH and Nasdaq: MTP, employs
c.100 staff in four countries. For further company information see:
www.midatechpharma.com
Forward-Looking Statements
Certain statements in this press release may constitute
"forward-looking statements" within the meaning of legislation in
the United Kingdom and/or United States. Any forward-looking
statements are based on currently available competitive, financial
and economic data together with management's views and assumptions
regarding future events and business performance as of the time the
statements are made and are subject to risks and uncertainties. We
wish to caution you that there are some known and unknown factors
that could cause actual results to differ materially from any
future results, performance or achievements expressed or implied by
such forward-looking statements.
Reference should be made to those documents that Midatech shall
file from time to time or announcements that may be made by
Midatech in accordance with the London Stock Exchange AIM Rules for
Companies ("AIM Rules"), the Disclosure and Transparency Rules
("DTRs") and the rules and regulations promulgated by the US
Securities and Exchange Commission, which contains and identifies
other important factors that could cause actual results to differ
materially from those contained in any projections or
forward-looking statements. These forward-looking statements speak
only as of the date of this announcement. All subsequent written
and oral forward-looking statements by or concerning Midatech are
expressly qualified in their entirety by the cautionary statements
above. Except as may be required under the AIM Rules or the DTRs or
by relevant law in the United Kingdom or the United States,
Midatech does not undertake any obligation to publicly update or
revise any forward-looking statements because of new information,
future events or otherwise arising.
63060366 v1
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCUGUBCQUPRUAG
(END) Dow Jones Newswires
June 01, 2018 02:00 ET (06:00 GMT)
Midatech Pharma (LSE:MTPH)
Historical Stock Chart
From Apr 2024 to May 2024
Midatech Pharma (LSE:MTPH)
Historical Stock Chart
From May 2023 to May 2024